{"id":4711,"date":"2025-03-31T18:12:17","date_gmt":"2025-03-31T18:12:17","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/tinzaparin-sodium-txt\/"},"modified":"2025-03-31T18:12:17","modified_gmt":"2025-03-31T18:12:17","slug":"tinzaparin-sodium-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/tinzaparin-sodium-txt\/","title":{"rendered":"tinzaparin sodium.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Peri- and postoperative surgical thromboprophylaxis Treatment of DVT and pulmonary embolism Prevention of thrombus formation in extracorporeal circulation during <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :

    DOSE IN NORMAL RENAL FUNCTION <\/H3> General surgery: (low-moderate risk) 3500 IU daily Orthopaedic surgery: (high risk) 50 IU\/kg or 4500 IU daily DVT and PE: 175 IU\/kg bodyweight once daily for at least 6 days and until adequate oral anticoagulation is established

    PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 5500\u20137500 (average 6500) <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 14 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 80\u201390 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 3.1\u20135 litres <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 1.5\/5.2 (detectable anti-Factor Xa activity persists for 24 hours)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Not dialysed. Dose as in GFR<20 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Not dialysed. Dose as in GFR<20 mL\/min
  • HDF\/high flux &nbsp : Dialysed. Dose as in GFR<20 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Not dialysed. Dose as in GFR=
  • 20 to 50<\/LI> mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Analgesics: increased risk of bleeding with NSAIDs \u2013 avoid concomitant use with IV diclofenac; increased risk of haemorrhage with ketorolac \u2013 avoid concomitant use\n
  • Nitrates: anticoagulant effect reduced by infusions of glyceryl trinitrate Drotrecogin alfa: manufacturer advises to avoid use of high doses of heparin with drotrecogin alfa Use with care in patients receiving oral anticoagulants, platelet aggregation inhibitors, aspirin or dextran

    Reconstition<\/H4> \u2013

    Route <\/H4> SC injection IV bolus\/infusion

    Rate of Administration <\/H4>

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> Tinzaparin is also indicated for prevention of clotting in the extracorporeal circulation during haemodialysis Dose for >4 hr session: IV bolus \u2014 (into arterial side of the dialyser or intravenously) of 3500\u20134500 IU Dose for 20 mL\/min for 10 days without any accumulation (Nagge J. Is impaired renal function a contraindication to the use of low-molecular weight heparin? Arch Intern Med. 2002; 162: 2605\u201309.) (Siguret V. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemostat. 2000; 84: 800\u201304.) Additional doses may be required if using LMWHs for anticoagulation in HDF Use 1 mg of protamine for every 100 anti-Xa IU to neutralise the effects of tinzaparin. If prothrombin time is still raised 2\u20134 hours later, give 0.5 mg\/kg infusion of protamine . TioGUAninE 729 Tioguanine
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Peri- and postoperative surgical thromboprophylaxis Treatment of DVT<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4711","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4711"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4711\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}